Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery

Cancer Biology and Therapy

Volumn 10, Issue 12, 2010, Pages 1290-1305

  Eulitt, Patrick J ^a   Park, Margaret A ^a   Hamed, Hossein A ^a   Cruikshanks, Nichola ^a   Yang, Chen ^a   Dmitriev, Igor P ^c   Yacoub, Adly ^a   Curiel, David T ^c   Fisher, Paul B ^a,b   Dent, Paul ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

AKT; ERK; Interleukin; JNK; Kidney; MAPK; MDA 7 IL 24; PERK; PI3K; RCC; Sorafenib

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FAS ANTIGEN; INTERLEUKIN 24; MAMMALIAN TARGET OF RAPAMYCIN; SORAFENIB;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CELL DEATH; CELL KILLING; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEROTYPE; SIGNAL TRANSDUCTION; TUMOR GENE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BCL-X PROTEIN; BENZENESULFONATES; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKINS; KIDNEY NEOPLASMS; MICE; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 78650349727     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.12.13497     Document Type: Article

References (44)

1. Sunela KL, Kataja MJ, Lehtinen ET, Salminen TK, Kujala PM, Virman JP, et al. Prognostic factors and long-term survival in renal cell cancer patients. Scand J Urol Nephrol 2009; 43:454-60.
2. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995; 11:2477-86.
3. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, et al. Downregulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 2001; 94:54-9.
4. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002; 20:1069-74.
5. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001; 20:7051-63.
6. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20 and 24 Signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277:47517-23.
7. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002; 168:6041-6.
8. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22:929-79.
9. Gupta P, Su ZZ, Lebedeva IV, Ekmekcioglu S, Mhashilkar AM, Yang XH, et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006; 111:596-628.
10. Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/ CD95/PERK-dependent mechanism. Mol Cancer Ther 2009; 8:1280-91.
11. Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/ IL-24 therapy of malignant glioma. Mol Ther 2010; 18:1130-42.
12. Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res 2010; 70:1120-9.
13. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Intl J Oncol 2007; 31:985-1007.
14. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 2009; 8:391-400.
15. Su ZZ, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001; 98:10332-7.
16. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998; 95:14400-5.
17. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005; 11:149-59.
18. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007; 224:300-7.
19. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002; 21:708-18.
20. L or bcl-2. Oncogene 2006; 25:2339-48.
21. Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitriev IP, et al. OSU-03012 enhances Ad.mda-7- induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther 2010; 9:526-36.
22. Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, et al. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95- dependent melanoma differentiation-associated gene- 7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol 2010; 77:298-310.
23. Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L, Randolph A, et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res 2006; 66:8182-91.
24. Sauane M, Gopalkrishnan RV, Choo Tt, Gupta P, Lebedeva IV, Yacoub A, et al. Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analyzed via a bacterial fusion protein. Oncogene 2004; 23:7679-90.
25. Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 2004; 3:739-51.
26. Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, et al. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther 2008; 7:917-33.
27. Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, et al. Caspase-, cathepsin- and PERKdependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 2008; 7:297-313. (Pubitemid 351302524)
28. Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, et al. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K and JNK1-3 pathway signaling. Mol Cancer Ther 2008; 7:314-29.
29. Yacoub A, Mitchell C, Brannon J, et al. MDA-7 (interleukin- 24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Mol Cancer Ther 2003; 2:623-32.
30. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002; 99:10054-9.
31. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8:207-19.
32. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, et al. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther 2005; 11:724-33.
33. Dash R, Dmitriev IP, Su ZZ, Bhutia SK, Azab B, Rahmani M, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther 2010; In press.
34. Murakami M, Ugai H, Belousova N, Pereboev A, Dent P, Fisher PB, et al. Chimeric adenoviral vectors incorporating A fiber of human adenovirus 3 efficiently mediate transgene expression into prostate cancer cells. Prostate 2010; 70:362-76.
35. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, et al. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 2008; 283:24343-58.
36. Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7:1648-62 37. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31.
37. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31.
38. Li N, Batt D, Warmuth M. B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 2007; 8:452-6.
39. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007; 7:617-26.
40. Gollob JA. Sorafenib: scientific rationales for singleagent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 2005; 4:167-74.
41. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005; 41:773-84.
42. Dash R, Richards JE, Su Zz, et al. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10 related cytokine. Cancer Res 2010; 70:5034-45.
43. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nature Rev Urol 2010; In press.
44. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312-8.